

## PCSK9 Monoclonal Antibody

**catalog number: AN200249P**

**Note:** *Centrifuge before opening to ensure complete recovery of vial contents.*


### Description

<b>Reactivity</b>	Rat
<b>Immunogen</b>	Recombinant Rat PCSK9 protein
<b>Host</b>	Mouse
<b>Isotype</b>	IgG1
<b>Clone</b>	11A5
<b>Purification</b>	Protein A
<b>Buffer</b>	0.2 µm filtered solution in PBS

### Applications Recommended Dilution

<b>IHC-P</b>	1:50-1:200
--------------	------------

### Data



Immunohistochemistry of paraffin-embedded rat brain using PCSK9 Monoclonal Antibody at dilution of 1:60.

### Preparation & Storage

<b>Storage</b>	This antibody can be stored at 2°C-8°C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20°C to -80°C. Preservative-Free. Avoid repeated freeze-thaw cycles.
<b>Shipping</b>	Ice bag

### Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels.

### For Research Use Only